Model N’s Michael Grosberg breaks down the accelerated complexity, policy disruption, and data gaps testing manufacturer market access and revenue management strategies. In the debut episode ...

Lilly’s Foundayo is reportedly off to a strong start. The company’s obesity only recently hit the market, and a report from ...

However, President Trump posted on his Truth Social account this morning that he is “pleased to announce the new leadership of the Centers for Disease Control and Prevention (CDC). It is my Honor to ...

Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...

Behavioral data indicate substantial underuse: ~40% delay epinephrine and 56% of caregivers fear needle-based auto-injectors, ...

In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...

In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in ...

, is a distinguished physician and epidemiologist with extensive experience in the pharmaceutical industry, global public health, digital health innovation, ...

Co-founder and CEO of Briya, a healthcare technology company supporting vital medical and biopharma research and innovation through proprietary AI and data solut ...

FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...

Formal triggers to reassess, restrict, or withdraw accelerated approvals are urged when postmarketing confirmatory trials lag ...

With the patent cliff looming, biosimilars can play an important role in the coming years. According to Newcomer, there are ...